Alembic
Touching Lives over 100 years

Date: 28th January, 2021

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai

Dear Sir,

Sub: Outcome of Board Meeting

With reference to the captioned subject, the exchange is hereby informed that the Board of Directors of Alembic Limited at its meeting held today has inter alia approved the Unaudited Financial Results of the Company for the quarter and nine months period ended on 31st December, 2020.

We enclose herewith the following:

1) Consolidated Unaudited Financial Results of the Company for the quarter and nine months period ended on 31st December, 2020.
2) Standalone Unaudited Financial Results of the Company for the quarter and nine months period ended on 31st December, 2020.
3) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results.

The time of commencement of the Board Meeting was 04:15 p.m. and the time of conclusion was 05:10 p.m.

We request you to kindly take the same on your record.

Thanking you.

Yours faithfully,
For Alembic Limited

Drigesh Mittal
Company Secretary

ALEMBIC LIMITED Vadodara

Encl.: A/a

ALEMBIC LIMITED
CIN:L26100GJ1907PLC000033
Regd.Office: Alembic Road, Vadodara 390 003
Ph:0265 2280550
www.alembiclimited.com Email:alembic.investors@alembic.co.in

Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2020

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Unaudited)	**31.12.2020 (Unaudited)**	31.12.2019 (Unaudited)	31.03.2020 (Audited)
1	**Revenue from Operations**	**1,448**	1,676	1,276	**4,463**	6,244	7,393
2	**Other Income**	**302**	268	206	**851**	3,613	9,340
3	**Total Income**	**1,750**	1,943	1,483	**5,314**	9,857	16,733
4	**Expenses**						
	Cost of Materials Consumed	**209**	310	147	**772**	2,220	2,459
	Cost of Construction	**91**	101	2	**192**	26	28
	Changes in Inventories of Finished Goods and WIP	**(136)**	64	208	**(0)**	778	684
	Employee Benefit Expenses	**559**	579	522	**1,759**	1,529	2,079
	Finance Costs	**10**	8	7	**27**	20	29
	Depreciation and amortisation expense	**102**	97	93	**291**	233	323
	Other Expenses	**335**	374	411	**1,028**	1,298	1,815
	Total Expenses	**1,170**	1,532	1,389	**4,068**	6,104	7,416
5	**Profit Before Tax**	**580**	411	94	**1,245**	3,754	9,317
6	**Tax Expenses**						
	Current Tax	**94**	91	-	**197**	-	-
	Deferred Tax	**(1)**	(2)	8	**29**	12	28
	Short / (Excess) Provision of earlier years	**-**	-	(7)	**-**	(15)	(15)
7	**Net Profit after tax for the Period**	**487**	322	92	**1,020**	3,756	9,303
8	**Share of Associate's Profit**	**8,072**	9,357	6,710	**26,071**	17,612	23,608
9	**Net Profit after tax and Share of Associate's Profit**	**8,559**	9,679	6,803	**27,090**	21,369	32,912
10	**Other Comprehensive Income**						
	A (i) Items that will not be reclassified to Profit or Loss	**(1,095)**	9,365	841	**11,827**	2,322	(2,230)
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	**130**	(1,067)	(104)	**(1,327)**	(263)	284
	B (i) Items that will be reclassified to Profit or Loss	**(18)**	(53)	8	**(79)**	122	225
11	**Total Comprehensive Income/(Loss) for the Period**	**7,575**	17,924	7,548	**37,511**	23,550	31,190
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	**5,135.64**	5,135.64	5,135.64	**5,135.64**	5,135.64	5,135.64
13	Other Equity (excluding Revaluation Reserve)						1,26,948
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	**3.33**	3.77	2.65	**10.55**	8.32	12.82

CNK & ASSOCIATES LLP VADODARA CHARTERED ACCOUNTANTS

ALEMBIC LIMITED Vadodara

Alembic Limited
Segment wise Consolidated Revenue and Results

Rs. In Lakhs

Sr. No.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Unaudited)	**31.12.2020 (Unaudited)**	31.12.2019 (Unaudited)	31.03.2020 (Audited)
1	**Segment Revenue**						
	Revenue from Operations						
	a. Active Pharmaceutical Ingredients Business	**564**	842	713	**2,133**	4,529	5,109
	b. Real Estate Business	**884**	833	563	**2,329**	1,715	2,284
	Total Income from Operations (Net)	**1,448**	1,676	1,276	**4,463**	6,244	7,393
2	**Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)**						
	a. Active Pharmaceutical Ingredients Business	**82**	4	(25)	**34**	256	155
	b. Real Estate Business	**336**	306	35	**742**	249	218
	Total	**418**	310	10	**776**	505	373
	Unallocable Income and Expenditure						
	(i) Interest Expense	**(10)**	(8)	(7)	**(27)**	(20)	(29)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	**61**	(9)	46	**204**	3,239	8,847
	(iii) Other Income / (Expense)	**111**	118	44	**292**	29	125
	Total Profit Before Tax	**580**	411	94	**1,245**	3,754	9,317
3	**Segment Assets**						
	a. Active Pharmaceutical Ingredients Business	**14,947**	14,876	15,074	**14,947**	15,074	20,414
	b. Real Estate Business	**17,263**	15,468	12,063	**17,263**	12,063	13,399
	c. Unallocated	**1,74,495**	1,68,307	1,18,317	**1,74,495**	1,18,317	1,13,259
	Total	**2,06,705**	1,98,651	1,45,454	**2,06,705**	1,45,454	1,47,072
4	**Segment Liabilities**						
	a. Active Pharmaceutical Ingredients Business	**1,730**	1,766	1,602	**1,730**	1,602	1,577
	b. Real Estate Business	**4,951**	4,302	3,080	**4,951**	3,080	3,522
	c. Unallocated	**1,560**	1,694	683	**1,560**	683	169
	Total	**8,241**	7,762	5,364	**8,241**	5,364	5,268

Notes:

1 The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.

2 During the quarter ended 31st December 2020, the Real Estate segment is slowly recovering back to normalcy. The API segment, being a part of essential services is largely unaffected.

The Company's management has made an internal assessment and believes that the impact is likely to be short term in nature and does not foresee any medium to long term risk in company's ability to continue as a going concern.

3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited

GNK & ASSOCIATES LLP VADODARA CHARTERED ACCOUNTANTS

ALEMBIC LIMITED Vadodara

Place : Vadodara
Date : 28th January, 2021

Chirayu Amin
Chairman

ALEMBIC LIMITED
CIN:L26100GJ1907PLC000033
Regd.Office: Alembic Road, Vadodara 390 003
Ph:0265 2280550
www.alembiclimited.com Email:alembic.investors@alembic.co.in

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2020

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Unaudited)	**31.12.2020 (Unaudited)**	31.12.2019 (Unaudited)	31.03.2020 (Audited)
1	**Revenue from Operations**	**1,418**	1,649	1,269	**4,376**	6,233	7,369
2	**Other Income**	**274**	269	208	**825**	3,618	9,347
3	**Total Income**	**1,692**	1,918	1,478	**5,201**	9,851	16,716
4	**Expenses**						
	Cost of Materials Consumed	**209**	310	147	**772**	2,220	2,459
	Cost of Construction	**91**	101	2	**192**	26	28
	Changes in Inventories of Finished Goods and WIP	**(136)**	64	208	**(0)**	778	684
	Employee Benefit Expenses	**559**	579	522	**1,759**	1,529	2,079
	Finance Costs	**8**	6	7	**20**	19	28
	Depreciation and amortisation expense	**102**	97	93	**291**	233	323
	Other Expenses	**317**	356	403	**969**	1,239	1,748
	Total Expenses	**1,149**	1,512	1,381	**4,002**	6,044	7,348
5	**Profit Before Tax**	**543**	407	97	**1,199**	3,807	9,368
6	**Tax Expenses**						
	Current Tax	**94**	91	-	**197**	-	-
	Deferred Tax	**(1)**	(2)	8	**29**	12	28
	Short / (Excess) Provision of earlier years	**-**	-	(7)	**-**	(15)	(15)
7	**Net Profit after tax for the Period**	**450**	317	95	**974**	3,809	9,355
8	**Other Comprehensive Income**						
	(i) Items that will not be reclassified to Profit or Loss	**(1,112)**	9,392	772	**12,032**	2,443	(1,894)
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	**133**	(1,071)	(93)	**(1,363)**	(284)	226
9	**Total Comprehensive Income/(Loss) for the Period**	**(530)**	8,638	775	**11,643**	5,968	7,687
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	**5,135.64**	5,135.64	5,135.64	**5,135.64**	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)						33,454
12	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	**0.18**	0.12	0.04	**0.38**	1.48	3.64

CNK & ASSOCIATES LLP VADODARA CHARTERED ACCOUNTANTS

ALEMBIC LIMITED Vadodara

Alembic Limited
Segment wise Standalone Revenue and Results

Rs. In Lakhs

Sr. No.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Unaudited)	**31.12.2020 (Unaudited)**	31.12.2019 (Unaudited)	31.03.2020 (Audited)
1	**Segment Revenue**						
	Revenue from Operations						
	a. Active Pharmaceutical Ingredients Business	**564**	842	713	**2,133**	4,529	5,109
	b. Real Estate Business	**854**	807	556	**2,243**	1,704	2,260
	Total Income from Operations (Net)	**1,418**	1,649	1,269	**4,376**	6,233	7,369
2	**Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)**						
	a. Active Pharmaceutical Ingredients Business	**82**	4	(25)	**34**	256	155
	b. Real Estate Business	**296**	299	35	**688**	249	269
	Total	**378**	303	10	**723**	505	424
	Unallocable Income and Expenditure						
	(i) Interest Expense	**(8)**	(6)	(7)	**(20)**	(19)	(28)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	**61**	(9)	46	**204**	3,239	8,847
	(iii) Other Income / (Expense)	**111**	118	47	**292**	82	125
	Total Profit Before Tax	**543**	407	97	**1,199**	3,807	9,368
3	**Segment Assets**						
	a. Active Pharmaceutical Ingredients Business	**14,947**	14,876	15,074	**14,947**	15,074	20,414
	b. Real Estate Business	**16,651**	15,240	12,063	**16,651**	12,063	13,288
	c. Unallocated	**34,825**	36,313	24,798	**34,825**	24,798	19,725
	Total	**66,423**	66,429	51,935	**66,423**	51,935	53,428
4	**Segment Liabilities**						
	a. Active Pharmaceutical Ingredients Business	**1,730**	1,766	1,602	**1,730**	1,602	1,577
	b. Real Estate Business	**4,721**	4,027	3,080	**4,721**	3,080	3,372
	c. Unallocated	**1,560**	1,694	663	**1,560**	663	169
	Total	**8,011**	7,487	5,344	**8,011**	5,344	5,118

Notes:

1 The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.

2 During the quarter ended 31st December 2020, the Real Estate segment is slowly recovering back to normalcy. The API segment, being a part of essential services is largely unaffected.

The Company's management has made an internal assessment and believes that the impact is likely to be short term in nature and does not foresee any medium to long term risk in company's ability to continue as a going concern.

3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited

CNK & ASSOCIATES LLP. VADODARA CHARTERED ACCOUNTANTS

ALEMBIC LIMITED Vadodara

Place : Vadodara
Date : 28th January, 2021

Chirayu Amin
Chairman

CNK & Associates LLP
Chartered Accountants

C - 201 - 202, Shree Siddhi Vinayak Complex, Opp. Alkapuri Side Railway Station, Faramji Road, Alkapuri, Vadodara - 390 005.
Ph. : +91-265-2343483, 2354353, 2354359
Email : alok@cnkindia.com

Independent Auditor's Review Report on Unaudited Consolidated Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Alembic Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 31st December, 2020 and year to date from 01st April, 2020 to 31st December, 2020 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable

4. The statement includes results of the following entities:

   i. Alembic City Limited (Subsidiary)
   ii. Alembic Pharmaceuticals Limited (Associate)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose unaudited financial results reflect total revenue of Rs. 150.54 lakhs and Rs. 365.75 lakhs, total net profit after tax of Rs. 9.54 Lakhs and total net loss after tax Rs. 29.96 lakhs and total comprehensive income of Rs. 9.61 Lakhs and total comprehensive loss of Rs. 29.33 lakhs for the quarter

CNK & ASSOCIATES VADODARA CHARTERED ACCOUNTANTS

ended 31st December, 2020 and the period ended on that day respectively. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs. 8,072.03 Lakhs and Rs. 26,070.55 lakhs and total comprehensive income of Rs. 8,068.07 lakhs and Rs. 25,821.82 lakhs for the quarter ended 31st December, 2020 and the period ended on that day respectively, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For **CNK & Associates LLP**
Chartered Accountants
Firm Registration No. 101961W/W-100036

CNK & ASSOCIATES LLP VADODARA CHARTERED ACCOUNTANTS

Alok Shah
Partner
Membership No. 042005
Place : Vadodara
Date : 28th January,2021
UDIN : 21042005AAAABZ7020

CNK & Associates LLP
Chartered Accountants

C - 201 - 202, Shree Siddhi Vinayak Complex, Opp. Alkapuri Side Railway Station,
Faramji Road, Alkapuri, Vadodara - 390 005.
Ph. : +91-265-2343483, 2354359
Email : alok@cnkindia.com

Independent Auditor's Review Report on Unaudited Standalone Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of **Alembic Limited** ("the Company") for the quarter ended 31st December,2020 and year to date from 01st April, 2020 to 31st December,2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For **CNK & Associates LLP**
Chartered Accountants
Firm Registration No. 101961W/W-100036

CNK & ASSOCIATES LLP VADODARA CHARTERED ACCOUNTANTS

Alok Shah
Partner
Membership No. 042005
Place : Vadodara
Date : 28th January,2021
UDIN : 21042005AAAABY4155